Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 76 to 90 of 193 results for transplantation

  1. Endobronchial valve insertion to reduce lung volume in emphysema (HTG457)

    Evidence-based recommendations on endobronchial valve insertion to reduce lung volume in emphysema. This involves placing small one-way valves in some airways leading to damaged parts of the lungs.

    HealthTech guidance
    Published
    20 December 2017
    View recommendations

    Sections for HTG457

  2. Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (TA218)

    Evidence-based recommendations on azacitidine (Vidaza) for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia in adults.

    Technology appraisal guidance
    Published
    23 March 2011
    View recommendations

    Sections for TA218

  3. Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)

    Evidence-based recommendations on atidarsagene autotemcel (Libmeldy) for treating metachromatic leukodystrophy in children.

    Highly specialised technologies guidance
    Published
    28 March 2022
    View recommendations

    Sections for HST18

  4. Autologous haematopoietic stem cell transplantation for treating multiple sclerosis [ID1111]

    Discontinued Reference number: GID-TA10306

    Technology appraisal guidance
    Discontinued

  5. Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause (HTG640)

    Evidence-based recommendations on removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause. This involves removing a small piece of ovarian tissue using keyhole surgery, freezing and storing it. After menopause starts, the tissue is thawed and transplanted under the skin of the armpit, abdomen or forearm, with the aim of producing oestrogen.

    HealthTech guidance
    Published
    21 September 2022
    View recommendations

    Sections for HTG640

  6. Mosaicplasty for symptomatic articular cartilage defects of the knee (HTG463)

    Evidence-based recommendations on mosaicplasty in people with symptomatic articular cartilage defects of the knee. This involves taking healthy cartilage from the edge of the joint and inserting it into drilled tunnels in the damaged site.

    HealthTech guidance
    Published
    14 March 2018
    View recommendations

    Sections for HTG463

  7. Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma (HTG489)

    Evidence-based recommendations on selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma in adults. This involves injecting tiny radioactive ‘beads’ into blood vessels that supply the liver, where they become trapped and release radiation directly into the cancer cells.

    HealthTech guidance
    Published
    31 October 2018
    View recommendations

    Sections for HTG489

  8. Partial left ventriculectomy (the Batista procedure) (HTG19)

    Evidence-based recommendations on partial left ventriculectomy. This involves reducing the size of a part of the heart so it can pump blood more efficiently.

    HealthTech guidance
    Published
    25 February 2004
    View recommendations

    Sections for HTG19

  9. Bortezomib for previously untreated mantle cell lymphoma (TA370)

    Evidence-based recommendations on bortezomib (Velcade) for untreated mantle cell lymphoma in adults.

    Technology appraisal guidance
    Published
    16 December 2015
    View recommendations

    Sections for TA370

  10. Bortezomib monotherapy for relapsed multiple myeloma (TA129)

    Evidence-based recommendations on bortezomib monotherapy (Velcade) for treating relapsed multiple myeloma in adults.

    Technology appraisal guidance
    Published
    23 October 2007
    View recommendations

    Sections for TA129

  11. Reducing the risk of complications of anticancer treatment in children and young people, and in adults diagnosed with lymphoma:- Randomised studies should investigate primary prophylaxis of neutropenic sepsis in 2 populations: children and young people (aged under 18) having treatment for solid tumours or haematological malignancies, or stem cell transplantation; and adults (aged 18 and older) diagnosed with lymphoma. The studies should compare the effectiveness of fluoroquinolone antibiotics given alone, fluoroquinolone antibiotics given together with G-CSF preparations, and G-CSF preparations given alone. Outcome measures should include overall mortality, infectious episodes and adverse events. In addition, quality of life should be determined using quantitative and qualitative methods. The resulting data should be used to develop a cost-effectiveness analysis comparing these 3 forms of prophylaxis in children and young people having anticancer treatment, and in adults diagnosed with lymphoma.

    treatment for solid tumours or haematological malignancies, or stem cell transplantation; and adults (aged 18 and older) diagnosed with...

    Research recommendation
    Published
    9 June 2015

  12. Everolimus for the treatment of prophylaxis of organ rejection in cardiac transplantation [ID114]

    Discontinued Reference number: GID-TAG232

    Technology appraisal guidance
    Discontinued

  13. Single-step scaffold insertion for repairing symptomatic chondral knee defects (HTG728)

    Evidence-based recommendations on single-step scaffold insertion for repairing symptomatic chondral knee defects. This involves inserting a scaffold into the damaged area of the knee to support regrowth and repair of the cartilage.

    HealthTech guidance
    Last updated
    5 August 2025
    View recommendations

    Sections for HTG728

  14. Ex-situ machine perfusion for extracorporeal preservation of lungs (ex-vivo lung perfusion) for transplant (HTG580)

    Evidence-based recommendations on ex-situ machine perfusion for extracorporeal preservation of lungs for transplant. This involves using a machine to deliver an oxygenated solution to a donor lung and keep it at normal body temperature until it can be transplanted.

    HealthTech guidance
    Published
    26 May 2021
    View recommendations

    Sections for HTG580

  15. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

    Evidence summary
    Published
    22 December 2015